Biomarkers in Young Patients With Acute Myeloid Leukemia
NCT ID: NCT01138332
Last Updated: 2015-05-06
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
20 participants
OBSERVATIONAL
2009-09-30
2010-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
PURPOSE: This research study is studying biomarkers in tissue samples from young patients with acute myeloid leukemia.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Studying Biomarkers in Cell Samples From Young Patients With Acute Myeloid Leukemia
NCT01057290
Biomarkers in Tissue Samples From Young Patients With Acute Myeloid Leukemia
NCT01229956
Drug Biomarkers in Cell Samples From Patients With Acute Myeloid Leukemia
NCT01150058
Biomarkers in Samples From Young Patients With Acute Myeloid Leukemia
NCT01138306
Study of Proteins in Promoting Chemotherapy Resistance in Samples From Patients With Acute Myeloid Leukemia
NCT01419496
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
* Determine the frequency of ligand-independent phosphorylation of Stat3 in a small cohort of samples from pediatric patients with acute myeloid leukemia including, but not limited to, samples known to express mutated c-kit.
* Measure the level of Stat3 phosphorylation in these samples after stimulation of three key cytokine receptors expressed on hematopoietic cells IL-6R, G-CSFR, and c-kit.
OUTLINE: Cryopreserved samples are analyzed for levels of various components of the Stat3 pathway via western blotting.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
RETROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
western blotting
laboratory biomarker analysis
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Diagnosis of acute myeloid leukemia
* One of the following karyotypes:
* t(8;21) and WT c-kit
* t(8;21) and mutant c-kit
* Normal karyotype
PATIENT CHARACTERISTICS:
* Not specified
PRIOR CONCURRENT THERAPY:
* Not specified
21 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Cancer Institute (NCI)
NIH
Children's Oncology Group
NETWORK
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Michele S. Redell, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Texas Children's Cancer Center
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
COG-AAML10B10
Identifier Type: OTHER
Identifier Source: secondary_id
CDR0000671489
Identifier Type: OTHER
Identifier Source: secondary_id
NCI-2011-02226
Identifier Type: REGISTRY
Identifier Source: secondary_id
AAML10B10
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.